陈李强, 沈欣然, 黄园*. 内质网靶向递药系统用于抗肿瘤免疫治疗的研究进展J. 药学学报, 2022,57(1): 76-84. doi: 10.16438/j.0513-4870.2021-1213
引用本文: 陈李强, 沈欣然, 黄园*. 内质网靶向递药系统用于抗肿瘤免疫治疗的研究进展J. 药学学报, 2022,57(1): 76-84. doi: 10.16438/j.0513-4870.2021-1213
CHEN Li-qiang, SHEN Xin-ran, HUANG Yuan*. Research progress of endoplasmic reticulum targeting drug delivery system for anti-tumor immunotherapyJ. Acta Pharmaceutica Sinica, 2022,57(1): 76-84. doi: 10.16438/j.0513-4870.2021-1213
Citation: CHEN Li-qiang, SHEN Xin-ran, HUANG Yuan*. Research progress of endoplasmic reticulum targeting drug delivery system for anti-tumor immunotherapyJ. Acta Pharmaceutica Sinica, 2022,57(1): 76-84. doi: 10.16438/j.0513-4870.2021-1213

内质网靶向递药系统用于抗肿瘤免疫治疗的研究进展

Research progress of endoplasmic reticulum targeting drug delivery system for anti-tumor immunotherapy

  • 摘要: 内质网作为真核细胞内功能多样的细胞器,不仅是蛋白质合成与修饰的关键场所,也是胞内信号转导的重要位点,影响着细胞的功能发挥、存活及凋亡。内质网稳态的失衡会引起内质网应激,这与肿瘤的发生与发展密不可分。在一些药物(蒽醌类及奥沙利铂等)的作用下,过度的内质网应激则会介导肿瘤细胞的免疫原性细胞死亡并激发抗肿瘤免疫反应,在治疗后期形成长期免疫记忆。但是,这些药物往往存在靶向性差等问题,在肿瘤细胞内质网的蓄积量极低,限制了其临床疗效。因此,内质网靶向药物的研究将为更高效更精准的抗肿瘤免疫治疗提供参考。本文就内质网与肿瘤免疫的关系,以及近年来基于内质网靶向的抗肿瘤免疫治疗的策略进行综述,并对内质网靶向策略存在的问题及未来发展方向进行总结与展望。

     

    Abstract: Endoplasmic reticulum (ER), a multifunctional organelle in eukaryotic cells, is responsible for protein synthesis and intracellular signal transduction, which dominates cell function, survival, and apoptosis. Disequilibrium of ER homeostasis may induce ER stress, which closely intertwines with tumor occurrence and progress. A few clinical-used drugs (such as anthraquinones and oxaliplatin) can mediate the immunogenic cell death of tumor cells through excessive ER stress, and sequentially stimulate anti-tumor immune responses as well as long-term immune memory. However, these drugs often exhibit poor targeting ability and extremely low ER accumulation in tumor cells, limiting their clinical efficacy. Therefore, the researches of ER-targeted delivery of these drugs will significantly benefit the efficient and precise anti-tumor immunotherapy. In this review, we introduce the relationship between ER and tumor immunity, and summarize the ER targeting strategies for anti-tumor immunotherapy in recent years. Furthermore, we discuss the problems of existing ER targeting strategies and look into its broad prospects of application.

     

/

返回文章
返回